ReShape Lifesciences Receives USPTO Issue Notification for Patent Covering its ReShape Vest
ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announces that the United States Patent and Trademark Office (“USPTO”) has issued an Issue Notification for U.S. Patent Number 10010441 entitled “Gastric Restriction Device for Treating Obesity,” which covers a patent application regarding the Company’s Gastric Vest System (the “ReShape Vest”). Barring any unforeseen circumstances, this patent will be valid until December 5, 2028.
The ReShape Vest, a new investigational medical device for weight loss in obese patients, wraps around the stomach and is designed to emulate conventional bariatric surgery without permanent anatomical changes. The ReShape Vest can be implanted in a minimally-invasive procedure with a goal to control weight gain and obesity. Patent No. 10010441 has broad claims directed to a skirt or a wrap that is shaped to form-fit and be securely fastened around the stomach of a patient to prevent expansion of the stomach.
“The ReShape Vest is a novel and ground-breaking advancement in the obesity space. This patent allowance represents a key milestone towards our launch of this revolutionary product for patients suffering from obesity and our physician customers who treat these patients” said Dan Gladney, Chairman and Chief Executive Officer of ReShape Lifesciences™. “The patent will provide intellectual property coverage to help ReShape Lifesciences secure a proprietary position in the market for decades as we move toward commercialization of this life- changing technology.”
About ReShape Lifesciences Inc.
ReShape Lifesciences™ is a medical device company focused on technologies to treat obesity and metabolic diseases. The FDA-approved ReShape Balloon™ System involves a non-surgical weight loss procedure that uses advanced balloon technology designed to take up room in the stomach to help people with a 30-40 kg/m2 Body Mass Index (BMI) and at least one co-morbidity lose weight. ReShape vBloc™ Therapy, delivered by an FDA-approved pacemaker-like device called the ReShape vBloc System, is designed to help patients with a 40-45 kg/m2, or a 35-39.9 kg/m2 BMI and at least one co-morbidity feel full and eat less by intermittently blocking hunger signals on the vagus nerve. The ReShape Vest™ System is an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery, and is intended to enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy.